---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-26-000003"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:50:02.257240+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Travere reports record Q4 FILSPARI sales of $103M; FSGS PDUFA decision due Jan 13

## Summary
- Preliminary Q4 2025 total U.S. net product sales ~$127M; FILSPARI sales ~$103M (+108% YoY).
- FY2025 total U.S. net product sales ~$410M; FILSPARI full-year sales ~$322M.
- Cash, equivalents and marketable securities ~$323M at year-end 2025.
- FSGS sNDA PDUFA target date Jan 13, 2026; responses to FDA's info requests submitted and under review.
- Pegtibatinase Phase 3 HARMONY study to restart in Q1 2026 after manufacturing optimization.

## SEC filing metadata
- accession: 0001438533-26-000003
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000003/0001438533-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000003/tvtx-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-26-000003
- JSON: https://secwatch.observer/filing/0001438533-26-000003.json
- Plain text: https://secwatch.observer/filing/0001438533-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.